This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
HealthdirectFree Australian health advice you can count on. — Description, Dosage, Side Effects | PillsCard
OTC
HealthdirectFree Australian health advice you can count on.
INN: daratumumab
Data updated: 2026-04-25
Available in:
🇨🇿🇬🇧🇫🇷🇵🇹🇷🇺🇸🇰
Form
—
Dosage
—
Route
—
Storage
—
About This Product
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
Manufacturer
Janssen-Cilag International N.V.
ATC Code
L01FC01
Source
EMA · EMEA/H/C/004077
(
ARTG
)
DARZALEX is indicated for the treatment of patients:
with newly diagnosed multiple myeloma:
- who are eligible for autologous stem cell transplant. For use in combination with:
bortezomib, thalidomide, and dexamethasone.
- who are ineligible for autologous stem cell transplant. For use in combination with:
bortezomib, melphalan and prednisone, or
lenalidomide and dexamethasone.
with relapsed or refractory multiple myeloma who have received:
- at least one prior therapy. For use in combination with:
bortezomib and dexamethasone, or
lenalidomide and dexamethasone.
carfilzomib and dexamethasone
- at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are refractory to both a PI and an immunomodulatory agent. For use as:
monotherapy.
